"Nevertheless," nonsense. They've had 1/3 (one out of three, in this case) of the cancer patients experience COMPLETE RESPONSE - they are cured (!) - and they still have three patients to complete the trial and be reported on. And then there are the partial responses that will be reviewed and could possibly be recategorized to complete responses. These are excellent results for a cancer treatment! The stock is hardly tanking, "bro," nor should it.
Market Data 
Markets 
AI
